The Clinical Efficacy and Safety of Ertapenem for the Treatment of Complicated Urinary Tract Infections Caused by ESBL-Producing Bacteria in Children

International Journal of Nephrology

Volumn 2015, Issue , 2015, Pages

  Karaaslan, Ayse ^a   Kadayifci, Eda Kepenekli ^a   Atici, Serkan ^a   Akkoc, Gulsen ^a   Yakut, Nurhayat ^a   Öcal Demir, Sevliya ^a   Soysal, Ahmet ^a   Bakir, Mustafa ^a  

^a MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84935825466     PISSN: 2090214X     EISSN: 20902158     Source Type: Journal    
DOI: 10.1155/2015/595840     Document Type: Article

References (20)

1. NICE (National Institute for Health and Care Excellence), "Urinary tract infection in children: diagnosis, treatment and long-term management, " Clinical Guideline 54, NICE, 2007.
2. S. Celebi, N. Yuce, D. C akir, M. Hacimustafaoglu, and G. Oakaya, "C ocuklarda genislemis spektrumluβ-laktamaz ureten E. coli enfeksiyonlarinda risk faktorleri ve klinik sonuclari, bes yillik calsma, " Cocuk EnfeksiyonHastaliklari Dernegi, vol. 3, pp. 5-10, 2009.
3. N. Demir, S. Gencer, S. Ozer, and M. Dogan, "Genislemis spektrumlu β-laktamaz ureten gram negatif bakteri infeksiyonlari icin cesitli risk fakorlerinin arastirilmasi, " Flora, vol. 13, pp. 179-188, 2008.
4. O. Kizilca, R. Siraneci, A. Yilmaz, et al., "Risk factors for community-acquired urinary tract infection caused by ESBLproducing bacteria in children, " Pediatrics International, vol. 54, no. 6, pp. 858-862, 2012.
5. UpToDate Database, http://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-inhibitors-carbapenemsandmonobactamssource=machineLearning&search=ertapenem&selectedTitle=5?36§ionRank=1&anchor=H3#H3.
6. G. M. Keating and C. M. Perry, "Ertapenem: a review of its use in the treatment of bacterial infections, " Drugs, vol. 65, no. 15, pp. 2151-2178, 2005.
7. J. S. Elder, "Urinary tract infections, " in Nelson Textbook of Pediatrics, R. M. Kliegman, R. Behrman, H. Jenson, and B. Stanton, Eds., chapter 538, pp. 2223-2228, Saunders Elsevier, Philadelphia, Pa, USA, 18th edition, 2007.
8. National Committee for Clinical Laboratory Stand ards, Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria ThatGrowAerobically, ApprovedStand ardM7-A5and Informational Supplement M100-S10, National Committee for Clinical Laboratory Stand ards, Wayne, Pa, USA, 2000.
9. M. D. Zilberberg and A. F. Shorr, "Secular trends in gramnegative resistance among urinary tract infection hospitalizations in the United States, 2000-2009, " Infection Control and Hospital Epidemiology, vol. 34, no. 9, pp. 940-946, 2013.
10. D. L. Paterson and R. A. Bonomo, "Extended-spectrum β-lactamases: a clinical update, " Clinical Microbiology Reviews, vol. 18, no. 4, pp. 657-686, 2005.
11. R. Ben-Ami, J. Rodrguez-Bano, H. Arslan, et al., "A multinational survey of risk factors for infection with extendedspectrum beta-lactamase-producing enterobacteriaceae in nonhospitalizd patients, " Clinical Infectious Diseases, vol. 49, no. 5, pp. 682-690, 2009.
12. N. Dalgic, M. Sancar, B. Bayraktar, E. Dincer, and S. Pelit, "Ertapenem for the treatment of urinary tract infections caused by extended-spectrum β-lactamase-producing bacteria in children, " Scand inavian Journal of Infectious Diseases, vol. 43, no. 5, pp. 339-343, 2011.
13. M. Fernand ez-Reyes, D. Vicente, M. Gomariz, et al., "High rate of fecal carriage of extended-spectrum-β-lactamase-producing Escherichia coli in healthy children in Gipuzkoa, northern Spain, " Antimicrobial Agents and Chemotherapy, vol. 58, no. 3, pp. 1822-1824, 2014.
14. T. M. Coque, F. Baquero, and R. Canton, "Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe, " Eurosurveillance, vol. 13, no. 47, article 4, 2008.
15. A. Parakh, S. Krishnamurthy, and M. Bhattacharya, "Ertapenem, " Kathmand u University Medical Journal, vol. 7, no. 28, pp. 454-460, 2009.
16. A. L. Freedman, "Urinary tract infections in children, " in Urologic Diseases in America. U. S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, M. S. Litwin and C. S. Saigal, Eds., NIH Publication 07-5512, pp. 439-458, U. S. Government Printing Office, Washington, DC, USA, 2007.
17. S. Hansson, I. Bollgren, E. Esbjorner, B. Jakobsson, and S. Marild, "Urinary tract infections in children below two years of age: a quality assurance project in Sweden, " Acta Paediatrica, vol. 88, no. 3, pp. 270-274, 1999.
18. E. Stokland, M. Hellstrom, B. Jacobsson, U. Jodal, and R. Sixt, "Evaluation of DMSA scintigraphy and urography in assessing both acute and permanent renal damage in children, " Acta Radiologica, vol. 39, no. 4, pp. 447-452, 1998.
19. H. Teppler, R. M. Gesser, I. R. Friedland, et al., "Safety and tolerability of ertapenem, " Journal of Antimicrobial Chemotherapy, vol. 53, supplement 2, pp. 75-81, 2004.
20. M. L. Currie, L. Mitz, C. S. Raasch, and L. A. Greenbaum, "Follow-up urine cultures and fever in children with urinary tract infection, " Archives of Pediatrics and Adolescent Medicine, vol. 157, no. 12, pp. 1237-1240, 2003.